Spero Therapeutics (SPRO) Scheduled to Post Earnings on Monday

Spero Therapeutics (NASDAQ:SPRO) is scheduled to announce its earnings results after the market closes on Monday, August 5th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.17). The firm had revenue of $9.27 million during the quarter, compared to analyst estimates of $16.80 million. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Trading Down 1.4 %

Shares of Spero Therapeutics stock traded down $0.02 on Tuesday, reaching $1.42. 20,251 shares of the company were exchanged, compared to its average volume of 224,253. The company has a market capitalization of $76.67 million, a price-to-earnings ratio of 3.35 and a beta of 0.63. The company has a 50-day moving average of $1.39 and a 200 day moving average of $1.52. Spero Therapeutics has a one year low of $0.99 and a one year high of $1.89.

Analysts Set New Price Targets

Several research firms recently commented on SPRO. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Spero Therapeutics in a report on Thursday, May 16th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.